Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corticotropin - Mallinckrodt

Drug Profile

Corticotropin - Mallinckrodt

Alternative Names: ACTH gel; Acthar; Acthar Gel; Adrenocorticotropin gel - Mallinckrodt; H.P. Acthar Gel; Repository corticotropin injection - Mallinckrodt

Latest Information Update: 29 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis Pharmaceuticals
  • Developer Mallinckrodt plc
  • Class Anterior pituitary hormones; Antiepileptic drugs; Corticosteroids; Hypothalamic hormones
  • Mechanism of Action Corticotropin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Infantile spasms
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal cortex disorders; Ankylosing spondylitis; Infantile spasms; Juvenile rheumatoid arthritis; Membranous glomerulonephritis; Multiple sclerosis; Nephrotic syndrome; Ocular inflammation; Polymyositis; Psoriatic arthritis; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 22 Oct 2018 Pharmacodynamics data from a preclinical study in Arthritis presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
  • 24 Jun 2018 Biomarkers information updated
  • 26 Jun 2017 Discontinued - Phase-II for Diabetic nephropathies in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top